AbbVie Inc. (ABBV)

Balance Sheet: Assets
Quarterly Data

Low level of difficulty

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

AbbVie Inc., consolidated balance sheet: assets (quarterly data)

US$ in millions

		Sep 30, 2019		Jun 30, 2019		Mar 31, 2019		Dec 31, 2018		Sep 30, 2018		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014
	Cash and equivalents
	Restricted cash
	Short-term investments
	Accounts receivable, net
	Inventories
	Deferred income taxes
	Prepaid expenses and other
	Current assets
	Investments
	Property and equipment, net
	Intangible assets, net
	Goodwill
	Other assets
	Noncurrent assets
	Total assets

Assets: Selected Items

Balance sheet item	Description	The company
Current assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	AbbVie Inc.’s current assets increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Property and equipment, net	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.	AbbVie Inc.’s property and equipment, net increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Noncurrent assets	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.	AbbVie Inc.’s noncurrent assets declined from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Total assets	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.	AbbVie Inc.’s total assets increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Current Assets: Selected Items

Balance sheet item	Description	The company
Cash and equivalents	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.	AbbVie Inc.’s cash and equivalents increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Short-term investments	Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.	AbbVie Inc.’s short-term investments declined from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Accounts receivable, net	Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.	AbbVie Inc.’s accounts receivable, net declined from Q1 2019 to Q2 2019 but then slightly increased from Q2 2019 to Q3 2019.
Inventories	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.	AbbVie Inc.’s inventories increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

	AbbVie Inc.	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Analysis of Financial Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis of Components of Financial Statements
Financial Reporting Quality

AbbVie Inc. (ABBV)

Balance Sheet: AssetsQuarterly Data

Assets: Selected Items

Current Assets: Selected Items

Balance Sheet: Assets
Quarterly Data